{
  "ticker": "IMU",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02959527",
  "id": "02959527",
  "pages": 3,
  "price_sensitive": false,
  "date": "20250618",
  "time": "0918",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250618/pdf/06kvndvsj2ymj3.pdf",
  "summary": "**Material Information Summary:**  \n\n- **US Patent Allowance**: Core patent granted for onCARlytics technology (CF33-CD19) in the US, valid until **August 10, 2038**.  \n- **IP Expansion**: Follows earlier patent allowance in China (2025), strengthening global IP position.  \n- **Trial Progress**: OASIS dose escalation trial ongoing in the US (up to 10 sites, ~40 patients).  \n\n*No material financial, capital raising, or trading halt details identified.*",
  "usage": {
    "prompt_tokens": 1178,
    "completion_tokens": 110,
    "total_tokens": 1288,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-17T23:30:15.705056"
}